SCHEMBL844974

SCHEMBL844974

CCOC(=O)c1c(C)cc(NC(=O)COCc2ccccc2)c(C(=O)O)c1C

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 1/20 0.52
KDM4E B2RXH2 3/20 0.51
HSD17B10 Q99714 2/20 0.51
POLB P06746 2/20 0.47
MAPK10 P53779 2/20 0.46
TSHR P16473 2/20 0.46
LMNA P02545 1/20 0.44
RAB9A P51151 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
KMT2A Q03164 2/20 0.43
ALDH1A1 P00352 2/20 0.43
NPC1 O15118 2/20 0.43
PTPRC P08575 1/20 0.42
PTPN1 P18031 1/20 0.42
MAPK8 P45983 1/20 0.42
MAPK9 P45984 1/20 0.42
TDP1 Q9NUW8 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CYP3A4 P08684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11368475 0.79 ALDH1A1 (0.48) KDM4EPOLBLMNARAB9ASMN1; SMN2
SCHEMBL844440 0.77 ALDH1A1 (0.46) KDM4EPOLBTSHRLMNARAB9A
SCHEMBL1828019 0.77 MAPT (0.48) KDM4EPOLBLMNASMN1; SMN2KMT2A
SCHEMBL11371087 0.74 MEN1 (0.46) KDM4EHSD17B10POLBTSHRRAB9A
SCHEMBL11377000 0.72 CYP3A4 (0.46) KDM4EPOLBTSHRLMNARAB9A
SCHEMBL12552814 0.71 NPC1 (0.64) RAB9ASMN1; SMN2KMT2ANPC1
SCHEMBL8697553 0.71 KDM4E (0.61) CSNK1DKDM4EHSD17B10POLBMAPK10
SCHEMBL8482565 0.70 KDM4E (0.73) CSNK1DKDM4EHSD17B10POLBLMNA
SCHEMBL12359416 0.69 PTPRC (0.59) KDM4EHSD17B10POLBRAB9ASMN1; SMN2
SCHEMBL8864405 0.68 PTPRC (0.59) CSNK1DRAB9ASMN1; SMN2KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8552015-B2 Quinazolinone derivatives and their use as CB agonists NOVARTIS AG (CH) 2013-10-08 US disclosed
EP-1472234-B1 QUINAZOLINONE DERIVATIVES AND THEIR USE AS CB AGONISTS NOVARTIS AG (CH) 2012-03-28 EP disclosed
EP-2319839-A1 Quinazolinone derivatives and their use as CB agonists Novartis AG (CH) 2011-05-11 EP disclosed
US-20070265285-A1 Quinazolinone derivatives and their use as CB agonists NOVARTIS AG (CH) 2007-11-15 US disclosed
US-20050085493-A1 Quinazolinone derivatives and their use as cb agonists BRAIN CHRISTOPHER T (GB) 2005-04-21 US disclosed
EP-1472234-A1 QUINAZOLINONE DERIVATIVES AND THEIR USE AS CB AGONISTS Novartis AG (CH) 2004-11-03 EP disclosed
WO-2003066603-A1 QUINAZOLINONE DERIVATIVES AND THEIR USE AS CB AGONISTS NOVARTIS AG (CH) 2003-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265285-A1 Quinazolinone derivatives and their use as CB agonists CNR1, ADRB1, ADRA1D CSNK1D 86/4885KDM4E 3258/4885HSD17B10 2465/4885
US-20050085493-A1 Quinazolinone derivatives and their use as cb agonists CNR1, ADRB1, ADRA2B CSNK1D 79/4885KDM4E 3214/4885HSD17B10 2385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.